Literature DB >> 27334520

CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population.

D L Fisher1, J Plange-Rhule2,3, M Moreton1, J B Eastwood4, S M Kerry5, F Micah3, A Johnston1, F P Cappuccio6, I A M MacPhee4.   

Abstract

CYP3A5 (cytochrome P450, family 3, subfamily A, polypeptide 5) expression stimulates the sodium retentive actions of the mineralocorticoid receptor causative of hypertension, probably by means of its ability to substantially increase the level of 6β-hydroxylase activity. Most Black individuals are functional CYP3A5 expressers, and this is a candidate gene for the high incidence of hypertension in Black populations. The study investigates whether CYP3A5 expression results in higher blood pressure in a Ghanaian population. Real-time PCR was used to genotype 898 DNA samples for the CYP3A5*3 and CYP3A5*6 single-nucleotide polymorphisms with technically adequate genotyping for 881 samples. Of these, 803 were genetic CYP3A5 expressers, 44 nonexpressers and 34 uncertain (CYP3A5*3/*6). Although there was a trend in the proportion of hypertensive individuals as CYP3A5 expression decreased, using a two-sided t-test, no statistically significant relationship was established between systolic or diastolic pressure and CYP3A5*3 or CYP3A5*6 genotypes, or their haplotypes (Systolic confidence interval: -8.44 to -7.70, P=0.93, Diastolic confidence interval: -4.89 to 4.85, P=0.99). We conclude, therefore, that there is either no association between CYP3A5 expression and blood pressure or, if there is a relationship, the strength of the association is very small.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27334520     DOI: 10.1038/jhh.2016.25

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  19 in total

1.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression.

Authors:  P Kuehl; J Zhang; Y Lin; J Lamba; M Assem; J Schuetz; P B Watkins; A Daly; S A Wrighton; S D Hall; P Maurel; M Relling; C Brimer; K Yasuda; R Venkataramanan; S Strom; K Thummel; M S Boguski; E Schuetz
Journal:  Nat Genet       Date:  2001-04       Impact factor: 38.330

2.  Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension.

Authors:  Bo Xi; Chunyu Wang; Liu Liu; Tao Zeng; Yajun Liang; Jun Li; Jie Mi
Journal:  Hypertens Res       Date:  2011-08-04       Impact factor: 3.872

Review 3.  Genetic contribution to variable human CYP3A-mediated metabolism.

Authors:  Jatinder K Lamba; Yvonne S Lin; Erin G Schuetz; Kenneth E Thummel
Journal:  Adv Drug Deliv Rev       Date:  2002-11-18       Impact factor: 15.470

Review 4.  The management of hypertensive disease in black patients.

Authors:  C R Gibbs; D G Beevers; G Y Lip
Journal:  QJM       Date:  1999-04

5.  Transepithelial sodium absorption is increased in people of African origin.

Authors:  E H Baker; N J Ireson; C Carney; N D Markandu; G A MacGregor
Journal:  Hypertension       Date:  2001-07       Impact factor: 10.190

6.  CYP3A5 mRNA degradation by nonsense-mediated mRNA decay.

Authors:  Florent Busi; Thierry Cresteil
Journal:  Mol Pharmacol       Date:  2005-06-13       Impact factor: 4.436

7.  A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy.

Authors:  D J Morris; S A Latif; M D Rokaw; C O Watlington; J P Johnson
Journal:  Am J Physiol       Date:  1998-05

8.  CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.

Authors:  Raymond C Givens; Yvonne S Lin; Amy L S Dowling; Kenneth E Thummel; Jatinder K Lamba; Erin G Schuetz; Paul W Stewart; Paul B Watkins
Journal:  J Appl Physiol (1985)       Date:  2003-05-16

9.  CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men.

Authors:  L Zhang; K Miyaki; W Wang; M Muramatsu
Journal:  J Hum Hypertens       Date:  2009-10-08       Impact factor: 3.012

10.  A community programme to reduce salt intake and blood pressure in Ghana [ISRCTN88789643].

Authors:  Francesco P Cappuccio; Sally M Kerry; Frank B Micah; Jacob Plange-Rhule; John B Eastwood
Journal:  BMC Public Health       Date:  2006-01-24       Impact factor: 3.295

View more
  3 in total

1.  Genetic factors contributing to hypertension in African-based populations: A systematic review and meta-analysis.

Authors:  Yandiswa Y Yako; Eric V Balti; Tandi E Matsha; Anastase Dzudie; Deirdre Kruger; Eugene Sobngwi; Charles Agyemang; Andre P Kengne
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-09       Impact factor: 3.738

2.  Influence of Genetic Admixture Components on CYP3A5*3 Allele-Associated Hypertension in Amerindian Populations From Northwest Mexico.

Authors:  Carlos Galaviz-Hernández; Blanca P Lazalde-Ramos; Ismael Lares-Assef; Alejo Macías-Salas; Margarita A Ortega-Chavez; Héctor Rangel-Villalobos; Martha Sosa-Macías
Journal:  Front Pharmacol       Date:  2020-05-11       Impact factor: 5.810

3.  Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease.

Authors:  Kevin A Lidberg; Andrew J Annalora; Marija Jozic; Daniel J Elson; Lu Wang; Theo K Bammler; Susanne Ramm; Maria Beatriz Monteiro; Jonathan Himmelfarb; Craig B Marcus; Patrick L Iversen; Edward J Kelly
Journal:  Sci Rep       Date:  2021-02-25       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.